Duloxetine in the treatment of major psychiatric and neuropathic disorders

References

• Davidson JR, Meltzer-Brody SE. The underrecognition and undertreatment of depression: what is the breadth and depth of the problem? J. Clin. Psychiatry60(Suppl. 7), 4–9; discussion 10–11 (1999).
   PubMed Web of Science ®Google Scholar
• Greden JF. The burden of recurrent depression: causes, consequences, and future prospects. J. Clin. Psychiatry62(Suppl. 22), 5–9 (2001).
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J. Clin. Psychiatry61(Suppl. 6), 4–6 (2000).
   PubMed Web of Science ®Google Scholar
• Schildkraut JJ. The catecholamine hypothesis of affective disorders. A review of supporting evidence. Int. J. Psychiatry4(3), 203–217 (1967).
   PubMedGoogle Scholar
• Stahl SM. The psychopharmacology of painful physical symptoms in depression. J. Clin. Psychiatry63(5), 382–383 (2002).
   PubMed Web of Science ®Google Scholar
• Greco T, Eckert G, Kroenke K. The outcome of physical symptoms with treatment of depression. J. Gen. Intern. Med.19(8), 813–818 (2004).
   PubMed Web of Science ®Google Scholar
• Bauer M, Möller H-J, Schneider E. Duloxetine: a new selective and dual-acting antidepressant. Expert Opin. Pharmacother.7(4), 421–427 (2006).
   PubMed Web of Science ®Google Scholar
• Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, Robertson DW. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology8(1), 23–33 (1993).
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology25(6), 871–880 (2001).
   PubMed Web of Science ®Google Scholar
• Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol.340(2–3), 249–258 (1997).
   PubMed Web of Science ®Google Scholar
• Koch S, Hemrick-Luecke SK, Thompson LK et al. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology45(7), 935–944 (2003).
   PubMed Web of Science ®Google Scholar
• Richelson E. The clinical relevance of antidepressant interaction with neurotransmitter transporters and receptors. Psychopharmacol. Bull.36(4), 133–150 (2002).
   PubMedGoogle Scholar
• Cymbalta® (duloxetine), prescribing information. Eli Lilly and company. Indianapolis, IN, USA (2005).
   Google Scholar
• Sharma A, Goldberg MJ, Cerimele BJ Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J. Clin. Pharmacol.40(2), 161–167 (2000).
   PubMed Web of Science ®Google Scholar
• Barkin RL, Barkin S. The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy. Am. J. Ther.12(5), 431–438 (2005).
   PubMedGoogle Scholar
• Skinner MH, Kuan HY, Pan A et al. Duloxetine in both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin. Pharmacol. Ther.57, 54–61 (2003).
   Google Scholar
• Lantz RJ, Gillespie TA, Rash TJ et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab. Dispos.31(9), 1142–1150 (2003).
   PubMed Web of Science ®Google Scholar
• Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J. Psychiatr. Res.39(1), 43–53 (2005).
   PubMed Web of Science ®Google Scholar
• Detke MJ, Lu Y, Goldstein DJ et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J. Clin. Psychiatry63(4), 308–315 (2002).
   PubMed Web of Science ®Google Scholar
• Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J. Psychiatr. Res.36(6), 383–390 (2002).
   PubMed Web of Science ®Google Scholar
• Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur. Neuropsychopharmacol.14(6), 457–470 (2004).
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J. Clin. Psychiatry63(3), 225–231 (2002).
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J. Clin. Psychopharmacol.24(4), 389–399 (2004).
   PubMed Web of Science ®Google Scholar
• Mallinckrodt CH, Goldstein DJ, Detke MJ, Lu Y, Tran PV. Duloxetine: a new treatment for the emotional and physical symptoms of depression. Primary Care Companion J. Clin. Psychiatry5, 19–28 (2003).
   Web of Science ®Google Scholar
• Perahia DGS, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur. Psychiatry21, 367–378 (2006).
   PubMed Web of Science ®Google Scholar
• Hudson JI, Perahia DG, Gilaberte I, Wang F, Watkin JG. Duloxetine in the treatment of major depressive disorder: an open-label study. BMC Psychiatry7, 43 (2007).
   PubMed Web of Science ®Google Scholar
• Pigott T, Prakash A, Arnold L, Aaronson S, Mallinckrodt CH, Wohlreich MM. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Curr. Med. Res. Opin.6, 1303–1318 (2007).
   Google Scholar
• Hamilton M. The Hamilton rating scale for depression. In: Assessment of Depression. Sartorius N, Ban TA (Eds). Springer, Berlin, Germany, 43–152 (1986).
   Google Scholar
• Hirschfeld RM, Vornik LA. Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine. J. Clin. Psychiatry65(Suppl. 4), 46–52 (2004).
   PubMed Web of Science ®Google Scholar
• Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr. Med. Res. Opin.7, 1605–1614 (2007).
   Google Scholar
• Wohlreich MM, Mallinckrodt CH, Watkin JG, Hay DP. Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study. BMC Geriatr.7(4), 11 (2004).
   Google Scholar
• Cookson J, Gilaberte I, Desaiah D, Kajdasz DK. Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat. Int. Clin. Psychopharmacol.21(5), 267–273 (2006).
   PubMed Web of Science ®Google Scholar
• Thase M, Lu Y, Joliat M, Detke M. Remission rates in double-blind, placebo-controlled clinical trials of duloxetine with SSRI as a comparator. Eur. Neuropsychopharmacol. (Suppl.), S259 (2006).
   Web of Science ®Google Scholar
• Swindle RW, Rosenbaum JR, Mallinckrodt CH et al. Efficacy of duloxetine treatment group: analysis of pooled data from six placebo-controlled clinical trials. Int. J. Neuropsychopharmacol.7(Suppl. 1), P02.177 (2004).
   Web of Science ®Google Scholar
• Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson MB. Duloxetine in the long-term treatment of major depressive disorder. J. Clin. Psychiatry64 (10), 1237–1244 (2003).
   PubMed Web of Science ®Google Scholar
• Eckert L, Lancon C. Duloxetine compared with fluoxetine and venlafaxine: use of meta-regresion analysis for indirect comparison. BMC Psychiatry24, 6–30 (2006).
   Google Scholar
• Vis P. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. Ann. Clin. Psychiatry39, 1798–1807 (2005).
   Google Scholar
• Hansen RA, Gartlehner G, Lohr KN, Gayes BN, Carey TS. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann. Intern. Med.143, 415–426 (2005).
   PubMed Web of Science ®Google Scholar
• Perahia DG, Pritchett YL, Kajdasz DK et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J. Psychiatr. Res.42(1), 22–34 (2007).
   PubMed Web of Science ®Google Scholar
• Simon GE, Von Korff M, Piccinelli M, Fullerton C, Ormel J. An international study of the relation between somatic symptoms and depression. N. Engl. J. Med.341(18), 1329–1335 (1999).
   PubMed Web of Science ®Google Scholar
• Posse M, Hallstrom T. Depressive disorders among somatizing patients in primary health care. Acta Psychiatr. Scand.98(3), 187–192 (1998).
   PubMed Web of Science ®Google Scholar
• Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch. Intern. Med.163, 2433–2445 (2003).
   PubMed Web of Science ®Google Scholar
• Fava M, Mallinckrodt CH, Detke Mj et al. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J. Clin. Psychiatry65, 521–530 (2004).
   PubMed Web of Science ®Google Scholar
• Desarkar P, Das A, Sinha V. Duloxetine for childhood depression with pain and dissociative symptoms. Eur. Child Adolesc. Psychiatry15(8), 496–499 (2006).
   PubMed Web of Science ®Google Scholar
• Meighen KG. Duloxetine treatment of pediatric chronic pain and co-morbid major depressive disorder. J. Child Adolesc. Psychopharmacol.17(1), 121–127 (2007).
   PubMed Web of Science ®Google Scholar
• Mogotsi M, Kaminer D, Stein DJ. Quality of life in anxiety disorders. Harv. Rev. Psychiatry8, 273–282 (2000).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. American Psychiatrics Press, Inc. Washington, DC, USA (1994).
   Google Scholar
• Hartford J, Kornstein S, Liebowitz MR et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial Int. Clin. Psychopharmacol.22(3), 167–174 (2007).
   PubMed Web of Science ®Google Scholar
• Koponen H, Allgulander C, Erickson J et al. Efficacy of duloxetine for treatment of generalized anxiety disorder: implications for primary care physicians. Prim. Care Companion J. Clin. Psychiatry9(2), 100–107 (2007).
   PubMedGoogle Scholar
• Rynn M, Russell KM, Erickson J et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress. Anxiety (2007) (Epub ahead of print).
   Google Scholar
• Endicott J, Russell J, Raskin J et al. Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies J. Clin. Psychiatry68, 518–524 (2007).
   PubMed Web of Science ®Google Scholar
• Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet. Med.21, 976–982 (2004).
   PubMed Web of Science ®Google Scholar
• Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity and impact on painful diabetic peripheral neuropathy in Type 2 diabetes. Diabetes Care29, 1518–1522 (2006).
   PubMed Web of Science ®Google Scholar
• Coderre TJ, Katz J. Peripheral and central hyperexcitability: differential signs and symptoms in persistent pain. Behav. Brain Sci.20, 404–419 (1997).
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs placebo in patients with painful diabetic neuropathy. Pain116, 109–118 (2005).
   PubMed Web of Science ®Google Scholar
• Raskin J, Pritcchett YL, Wang F et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med.6, 346–356 (2005).
   PubMed Web of Science ®Google Scholar
• Wernicke JF, Pritchett YL, D’Souza DN et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology67, 1411–1420 (2006).
   PubMed Web of Science ®Google Scholar
• Ziegler D, Pritchett YL, Wang F et al. Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. Diabetes Care30, 664–669 (2007).
   PubMed Web of Science ®Google Scholar
• Hardy T, Sachson R, Shen S, Armbruster M, Boulton AJM. Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care30, 21–26 (2007).
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin. Drug Saf.5, 157–168 (2006).
   PubMed Web of Science ®Google Scholar
• Lembo G, Capaldo B, Rendina V et al. Acute noradrenergic activation induces insulin resistance in human skeletal muscle. Am. J. Physiol.266, E242–E247 (1994).
   PubMed Web of Science ®Google Scholar
• Wernicke JF, Rosen AS, Pritchett YL, Souza DN, Westell DJ, Arnold LM. Duloxetine in the treatment of women with fibromyalgia. Presented at: The 158th Annual Meeting of the American Psychiatric Association. Atlanta, GA, USA 21–26 May 2005 (NR860).
   Google Scholar
• Arnold LM, Lu Y, Crofford LJ et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum.50, 2974–2984 (2004).
   PubMed Web of Science ®Google Scholar
• Rooks DS. Fibromyalgia treatment update. Curr. Opin. Rheumatol.19, 111–117 (2007).
   PubMed Web of Science ®Google Scholar
• Hampel C, Artibani W, Espuna Pons M et al. Understanding the burden of stress urinary incontinence in Europe: a qualitative review of the literature. Eur. Urol.46(1), 15–27 (2004).
   PubMed Web of Science ®Google Scholar
• Kinchen KS, Burgio K, Diokno AC, Fultz NH, Bump RC. Burden of stress urinary incontinence for community-dwelling women. Am. J. Obstet. Gynecol.189, 1275–1282 (2003).
   PubMed Web of Science ®Google Scholar
• Hunskaar S, Lose G, Sykes D, Voss S. The prevalence of urinary incontinence in women in four European countries. BJU Int.93, 324–330 (2004).
   PubMed Web of Science ®Google Scholar
• Boy S, Reitz A, Wirth B et al. Facilitatory neuromodulative effect of duloxetine on pudendal motor neurons controlling the urethral pressure: a functional urodynamic study in healthy women. Eur. Urol.50(1), 119–125 (2006).
   PubMed Web of Science ®Google Scholar
• Athanasiou S, Chaliha C, Digesu GA et al. The effects of duloxetine on urethral function and spincter morphology. Int. Urogynecol. J. Pelvic Floor Dysfunct.18(7), 763–767 (2006).
   PubMed Web of Science ®Google Scholar
• Thor KB. Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence. Urology62(4 Suppl. 1), 3–9 (2003).
   PubMedGoogle Scholar
• Thor KB, Katofiasc MA. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J. Pharmacol. Exp. Ther.274(2), 1014–1024 (1995).
   PubMed Web of Science ®Google Scholar
• Cardozo L, Drutz HP, Baygani SK, Bump RC. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstet. Gynecol.104(3), 511–519 (2004).
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J. Urol.170(4 Part 1), 1259–1263 (2003).
   PubMed Web of Science ®Google Scholar
• Ghoniem GM, Van Leeuwen JS, Elser DM et al. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J. Urol.173(5), 1647–1653 (2005).
   PubMed Web of Science ®Google Scholar
• Kinchen KS, Obenchain R, Swindle R. Impact of duloxetine on quality of life for women with symptoms of urinary incontinence. Int. Urogynecol. J. Pelvic Floor Dysfunct.16(5), 337–344 (2005).
   PubMed Web of Science ®Google Scholar
• Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int.93(3), 311–318 (2004).
   PubMed Web of Science ®Google Scholar
• Mulcahy JJ, Laddu AR, Faries DE et al. Efficacy and safety of duloxetine in stress incontinence patients. Neurourol. Urodyn.15, 395–396 (1996).
   Google Scholar
• Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine Urinary Incontinence Study Group: duloxetine versus placebo in the treatment of stress urinary incontinence. Am. J. Obstet. Gynecol.187(1), 40–48 (2002).
   PubMed Web of Science ®Google Scholar
• van Kerrebroeck P, Abrams P, Lange R et al. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG111(3), 249–257 (2004).
   PubMed Web of Science ®Google Scholar
• Zinner N, Sarshik S, Yalcin I et al. Evaluation of various efficacy measures from 140 stress and 146 mixed incontinence patients enrolled in a double-blind, placebo-controlled trial of duloxetine. In: Proceedings of International Continence Society.175–176 (1998).
   Google Scholar
• Penson DF, McLerran D, Feng Z et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J. Urol.173(5), 1701–1705 (2005).
   PubMed Web of Science ®Google Scholar
• Imamoglu MA, Tuygun C, Bakirtas H, Yigitbasi O, Kiper A. The comparison of artificial urinary sphincter implantation and endourethral macroplastique injection for the treatment of postprostatectomy incontinence. Eur. Urol.47(2), 209–213 (2005).
   PubMed Web of Science ®Google Scholar
• Schlenker B, Gratzke CH, Reich O, Schorsch I, Seitz M, Stief CG. Preliminary results on the off-label use of duloxetine for the treatment of stres incontinence after radical prostatectomy or cystectomy. Eur. Urol.49, 1075–1078 (2006).
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr. Pharm. Des.11(12), 1475–1493 (2005).
   PubMed Web of Science ®Google Scholar
• Greist J, McNamara RK, Mallickrodt CH et al. Incidence and duration of antidepressant-induceded nausea: duloxetine compared with paroxetine and fluoxetine. Clin. Ther.26, 1446–1455 (2004).
   PubMed Web of Science ®Google Scholar
• Thase ME, Tran PV, Wiltse C et al. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J. Clin. Psychopharmacol.25, 132–140 (2005).
   PubMed Web of Science ®Google Scholar
• Wernicke J, Lledo A, Raskin J, Kajdasz DK, Wang F. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf.30(5), 427–455 (2007).
   Google Scholar
• Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium. J. Clin. Psychopharmacol.8(5), 323–330 (1988).
   PubMed Web of Science ®Google Scholar
• Raskin J, Goldstein DJ, Mallickrodt CH, Ferguson MB. Duloxetine in the long-term treatment of major depressive disorder. J. Clin. Psychiatry64, 1237–1244 (2003).
   PubMed Web of Science ®Google Scholar
• Wise TN, Perahia DGS, Pangallo BRN, Losin WG, Wiltse CG. Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. Prim. Care Companion. J. Clin. Psychiatry8(5), 269–278 (2006).
   PubMedGoogle Scholar
• Ferguson JM. The effects of antidepressants on sexual functioning in depressed patients: a review. J. Clin. Psychiatry62(Suppl. 3), 22–34 (2001).
   PubMed Web of Science ®Google Scholar
• Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J. Clin. Psychopharmacol.19(1), 67–85 (1999).
   PubMed Web of Science ®Google Scholar
• Brannan SK, Detke MJ, Wang F, Mallinckrodt CH, Tran PV, Delgado PL. Comparison of sexual functioning in patients receiving duloxetine of paroxetine: acute – and long-term data. Presented at: The 156th American Psychiatric Association Meeting. San Francisco, CA, USA, 17 May, 2003 (Abstract NR477).
   Google Scholar
• Delgado P, Brannan S, Mallickrodt CH et al. Sexual functioning assessed in 4 double-blind placebo – and paroxetin-controlled trials of duloxetine for major depressive disorder. J. Clin. Psychiatry66, 686–692 (2005).
   PubMed Web of Science ®Google Scholar
• Hudson JI, Wohlreich MW, Kajdasz DK, Mallinckrodt CH, Watkin JG, Martynov OV. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum. Psychopharmacol. Clin. Exp.20, 327–341 (2005).
   PubMed Web of Science ®Google Scholar